Lexaria Bioscience: Advancing Next-Generation Oral Weight-Loss Drugs

Improving GLP-1 tolerability through patented oral delivery technology

The next generation of weight-loss treatments could be defined not only by how well they work, but by how easy they are for patients to tolerate and take.

Lexaria Bioscience is targeting both challenges with its patented oral drug delivery technology. In clinical studies, Lexaria’s technology reduced side effects associated with established GLP-1 drugs by up to 50%, pointing to the potential for a better-tolerated oral treatment experience.

As pharmaceutical companies compete to develop next-generation weight-loss therapies, reducing common side effects while moving away from injections could play an important role in expanding patient adoption.

Lexaria is positioning its technology within this rapidly growing market as a potential delivery solution for established and future GLP-1 therapies.

The company recently announced its latest pharmaceutical partner, adding momentum to its development strategy and providing further validation for its technology within the multi-billion-dollar GLP-1 market.

Rather than competing to develop a single weight-loss drug, Lexaria is focused on the technology that could help make next-generation oral therapies easier for patients to take and tolerate.

For more information on Lexaria Bioscience Corp. (NASDAQ: LEXX) please click on the request investor info button.